AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...
While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...
Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...
US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...
Ads during women's sports programs were 40% more impactful than the average primetime advertisement, according to EDO.
AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech ...
GlobalData on MSN20h
J&J and Protagonist’s icotrokinra scores in Phase IIb UC studyGlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback